At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 48 enrolled
Drug / intervention
ABBV-3373 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Double-Dummy, Active Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Subjects With Moderate to Severe Rheumatoid Arthritis
In Brief
A Phase 2 clinical trial evaluating ABBV-3373, Placebo for ABBV-3373, and 2 other interventions for Rheumatoid Arthritis (RA). Completed, enrolled 48 participants across 30 sites in 7 countries.
Detailed Summary
This study will assess the safety, tolerability, and efficacy of ABBV-3373 in participants with moderately to severely active rheumatoid arthritis (RA) on background methotrexate (MTX) compared with adalimumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis (RA)
CountriesGermany, Hungary, Israel, Netherlands, Poland, Puerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartMar 2019
Primary CompletionApr 2020
Study CompletionAug 2020
TodayJul 2026
First PostedJan 30, 2019
Enrollment StartMar 27, 2019
Primary CompletionApr 8, 2020
Study CompletionAug 26, 2020
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.4 years ago
Interventions
ABBV-3373drug
ABBV-3373 is administered as intravenous (IV) infusion
Placebo for ABBV-3373drug
Placebo for ABBV-3373 is administered as IV infusion
Adalimumabdrug
Adalimumab is administered as subcutaneous (SC) injection
Placebo for adalimumabdrug
Placebo for adalimumab is administered as subcutaneous (SC) injection